Payment overview · 2025
General Payments
$1,400.44
74 reported records · 25 companies
Healthcare provider profile · identity verified
Christopher C Kang, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · JOHNS CREEK, GA · NPI 1447226808
Verified facts
What the public records show
CMS Open Payments records show Christopher C Kang, M.D. received $1,400.44 in general payments during 2025 across 74 reported records.
ABBVIE INC. accounted for 17.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Edarbyclor, Gemtesa, Linzess, Mounjaro, Ozempic, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 253 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 237 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Farxiga by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBI as an associated drug or biological on 1140 records involving 805 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Edarbi by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBYCLOR as an associated drug or biological on 283 records involving 215 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Edarbyclor by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Vemlidy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $241.42 | 17.2% | 11 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $173.76 | 12.4% | 10 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $165.69 | 11.8% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $135.01 | 9.6% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $81.20 | 5.8% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $61.93 | 4.4% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $60.95 | 4.3% | 3 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $46.99 | 3.4% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$46.94 | 3.4% | 1 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $39.40 | 2.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $38.48 | 2.8% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $38.37 | 2.7% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $31.26 | 2.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $28.99 | 2.1% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $26.91 | 1.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.58 | 1.6% | 5 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.38 | 1.6% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.56 | 1.5% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $19.01 | 1.4% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $18.66 | 1.3% | 1 | 2025 |
| Vital Connect, Inc | Unresolved — no canonical attribution shown | $17.84 | 1.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.27 | 1.2% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.61 | 1.1% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $15.31 | 1.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.92 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,400.44 | 74 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $183.35 | 8 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $183.35 | 8 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $165.69 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $112.44 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $62.59 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $61.93 | 3 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $60.95 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $58.07 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $58.07 | 3 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $46.94 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $42.58 | 2 | 2025 |
Source payment records
|
|||||
| FIBRYGA Normalized: fibryga |
Biological | Octapharma USA, Inc. | $39.40 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $38.48 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $38.37 | 2 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $33.13 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $31.26 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $26.91 | 1 | 2025 |
Source payment records
|
|||||
| PANCREAZE Normalized: pancreaze |
Drug | VIVUS LLC | $25.32 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $22.58 | 5 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $22.38 | 1 | 2025 |
Source payment records
|
|||||
| QSYMIA Normalized: qsymia |
Drug | VIVUS LLC | $21.67 | 1 | 2025 |
Source payment records
|
|||||
| EDARBYCLOR Normalized: edarbyclor |
Drug | Azurity Pharmaceuticals, Inc. | $20.56 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $19.01 | 1 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| VITALPATCH RTM Normalized: vitalpatch rtm |
Device | Vital Connect, Inc | $17.84 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.89 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.89 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.10 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.92 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $5.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 253 | exact normalized | Medicare Part D |
| EDARBYCLOR edarbyclor |
2025 | Edarbyclor | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 24 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 53 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 37 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 71 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
253 | 65 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
53 | 21 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
237 | 137 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
37 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBI open payments reported associated product |
CMS Open Payments — General Payments 1140 supporting records · 805 recipient NPIs · example record 1242666830 |
Edarbi · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBYCLOR open payments reported associated product |
CMS Open Payments — General Payments 283 supporting records · 215 recipient NPIs · example record 1242666846 |
Edarbyclor · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
149 | 46 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
37 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
71 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
60 | 13 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
24 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1177 | 372 |
| Amlodipine Besylate | Amlodipine Besylate | 1094 | 346 |
| Losartan Potassium | Losartan Potassium | 841 | 254 |
| Metformin Hcl | Metformin Hcl | 815 | 242 |
| Alendronate Sodium | Alendronate Sodium | 394 | 134 |
| Vascepa | Icosapent Ethyl | 377 | 86 |
| Tamsulosin Hcl | Tamsulosin Hcl | 371 | 124 |
| Omeprazole | Omeprazole | 367 | 120 |
| Levothyroxine Sodium | Levothyroxine Sodium | 366 | 115 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 322 | 113 |
| Lisinopril | Lisinopril | 311 | 87 |
| Pantoprazole Sodium | Pantoprazole Sodium | 303 | 102 |
| Donepezil Hcl | Donepezil Hcl | 293 | 95 |
| Glimepiride | Glimepiride | 276 | 77 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 263 | 127 |
| Creon | Lipase/Protease/Amylase | 253 | 65 |
| Prolia | Denosumab | 237 | 137 |
| Simvastatin | Simvastatin | 221 | 67 |
| Pravastatin Sodium | Pravastatin Sodium | 205 | 64 |
| Escitalopram Oxalate | Escitalopram Oxalate | 199 | 77 |
| Zolpidem Tartrate | Zolpidem Tartrate | 198 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 182 | 52 |
| Meloxicam | Meloxicam | 179 | 110 |
| Fenofibrate | Fenofibrate | 161 | 50 |
| Jardiance | Empagliflozin | 149 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 139 | 44 |
| Finasteride | Finasteride | 135 | 43 |
| Metformin Hcl Er | Metformin Hcl | 134 | 46 |
| Azithromycin | Azithromycin | 127 | 110 |
| Gabapentin | Gabapentin | 115 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 114 | 59 |
| Famotidine | Famotidine | 110 | 38 |
| Alprazolam | Alprazolam | 108 | 47 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 107 | 33 |
| Diclofenac Sodium | Diclofenac Sodium | 106 | 54 |
| Metoprolol Tartrate | Metoprolol Tartrate | 105 | 33 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 92 | 70 |
| Januvia | Sitagliptin Phosphate | 91 | 22 |
| Lidocaine | Lidocaine | 91 | 21 |
| Tramadol Hcl | Tramadol Hcl | 85 | 33 |
| Trazodone Hcl | Trazodone Hcl | 85 | 27 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 78 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 74 | 20 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 73 | 32 |
| Allopurinol | Allopurinol | 71 | 21 |
| Lovastatin | Lovastatin | 71 | 21 |
| Methylprednisolone | Methylprednisolone | 71 | 69 |
| Ozempic | Semaglutide | 71 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 64 | 54 |
| Carvedilol | Carvedilol | 62 | 17 |
| Montelukast Sodium | Montelukast Sodium | 62 | 20 |
| Eliquis | Apixaban | 60 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 58 | 16 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 58 | 37 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 55 | 22 |
| Glipizide Er | Glipizide | 54 | 15 |
| Atenolol | Atenolol | 53 | 16 |
| Labetalol Hcl | Labetalol Hcl | 53 | 11 |
| Linzess | Linaclotide | 53 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 17 |
| Glipizide | Glipizide | 50 | 16 |
| Ketoconazole | Ketoconazole | 50 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 42 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 41 | 12 |
| Farxiga | Dapagliflozin Propanediol | 39 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 16 |
| Celecoxib | Celecoxib | 37 | 18 |
| Mounjaro | Tirzepatide | 37 | 12 |
| Myrbetriq | Mirabegron | 37 | 11 |
| Zenpep | Lipase/Protease/Amylase | 36 | suppressed |
| Valsartan | Valsartan | 35 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | 11 |
| Furosemide | Furosemide | 34 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 33 | 14 |
| Synthroid | Levothyroxine Sodium | 33 | suppressed |
| Ezetimibe | Ezetimibe | 32 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 29 |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 31 | suppressed |
| Memantine Hcl | Memantine Hcl | 31 | suppressed |
| Potassium Chloride | Potassium Chloride | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 27 |
| Sucralfate | Sucralfate | 30 | 12 |
| Terazosin Hcl | Terazosin Hcl | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Restasis | Cyclosporine | 28 | suppressed |
| Cephalexin | Cephalexin | 27 | 22 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Edarbi | Azilsartan Medoxomil | 26 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 24 | 14 |
| Gemtesa | Vibegron | 24 | 11 |
| Tradjenta | Linagliptin | 24 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 15 |
| Azelastine Hcl | Azelastine Hcl | 22 | 13 |
| Latanoprost | Latanoprost | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 18 |
| Spironolactone | Spironolactone | 21 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 20 | 20 |
| Ciclopirox | Ciclopirox | 20 | suppressed |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 20 | suppressed |
| Livalo | Pitavastatin Calcium | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Dutasteride | Dutasteride | 19 | suppressed |
| Minoxidil | Minoxidil | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Ursodiol | Ursodiol | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 16 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 12 | suppressed |
| Tenivac | Tetanus-Diphtheria Toxoids/Pf | 12 | 12 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,400.44 · 74 records | ABBVIE INC. | ACCRUFER, AIRSUPRA, Bimzelx, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, EDARBYCLOR, EVENITY, FIBRYGA, FREESTYLE LIBRE 3, GEMTESA, INTELLIS ADAPTIVESTIM, Korlym, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PANCREAZE, QSYMIA, QULIPTA, REPATHA, Rybelsus, UBRELVY, ULTOMIRIS, VIBERZI, VITALPATCH RTM, VOQUEZNA, Veozah, ZAVZPRET, ZENPEP, ZEPBOUND, ZORYVE, ZTLido | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error